Alshetaili Abdullah S, Ali Raisuddin, Qamar Wajhul, Almohizea Salman, Anwer Md Khalid
Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, P.O. Box 173, Al-Kharj 11942, Saudi Arabia.
Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
Int J Biol Macromol. 2023 Aug 15;246:125679. doi: 10.1016/j.ijbiomac.2023.125679. Epub 2023 Jul 3.
In total, nine TPGS-b-PCL copolymers were synthesized employing distinct TPGS analogues (TPGS 2000, 3500, and 5000). In these copolymers, the length of the PCL chain varied according to the TPGS to PCL molecular weight ratio (1:1, 1:2, and 1:3). The formulation optimization was done by optimizing the drug to polymer ratio, encapsulation efficiency, drug loading, micelle diameter, and polydispersity index (PDI). TPGS3500-b-PCL7000 copolymer (TPGS to PCL ratio 1:2) with drug to polymer ratio 1:30 showed the best percentage encapsulation (63.50 ± 0.45 %) and drug loading (2.05 ± 0.07). The optimal micelle (CHR-M) diameter and PDI were determined to be 94.57 ± 13.40 nm and 0.16 ± 0.02, respectively. CHR-M showed slow release when compared with alcoholic solution of chrysin. Approximately 70.70 ± 6.4 % drug was released in 72 h. The CHR-M demonstrated considerably greater absorption in Hep G2 cells, which confirmed the reliability of the micellar carrier. The MTT assay results showed that the IC values for CHR-M were much lower after 24 and 48 h when compared to free chrysin. Therefore, CHR-M may be a viable carrier for active chrysin targeting with improved anticancer potential. Also, it could be a better alternative for the currently available treatment of hepatocellular carcinoma.
总共使用不同的TPGS类似物(TPGS 2000、3500和5000)合成了九种TPGS-b-PCL共聚物。在这些共聚物中,PCL链的长度根据TPGS与PCL的分子量比(1:1、1:2和1:3)而变化。通过优化药物与聚合物的比例、包封效率、载药量、胶束直径和多分散指数(PDI)进行配方优化。药物与聚合物比例为1:30的TPGS3500-b-PCL7000共聚物(TPGS与PCL比例为1:2)显示出最佳的包封率(63.50±0.45%)和载药量(2.05±0.07)。确定最佳胶束(CHR-M)直径和PDI分别为94.57±13.40nm和0.16±0.02。与白杨素的醇溶液相比,CHR-M显示出缓释特性。在72小时内约70.70±6.4%的药物被释放。CHR-M在Hep G2细胞中表现出显著更高的吸收,这证实了胶束载体的可靠性。MTT分析结果表明,与游离白杨素相比,CHR-M在24小时和48小时后的IC值要低得多。因此,CHR-M可能是一种可行的载体,用于活性白杨素靶向,具有提高的抗癌潜力。此外,它可能是目前肝细胞癌治疗方法的更好替代方案。